Fleur S van de Bovenkamp
Overview
Explore the profile of Fleur S van de Bovenkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, van de Bovenkamp F, Dijkstra D, Abendstein L, Borggreven N, Pool J, et al.
Front Immunol
. 2024 May;
15:1288597.
PMID: 38817607
Complement activation protects against infection but also contributes to pathological mechanisms in a range of clinical conditions such as autoimmune diseases and transplant rejection. Complement-inhibitory drugs, either approved or in...
2.
Abendstein L, Noteborn W, Veenman L, Dijkstra D, van de Bovenkamp F, Trouw L, et al.
J Am Chem Soc
. 2024 May;
146(19):13455-13466.
PMID: 38703132
The classical complement pathway is activated by antigen-bound IgG antibodies. Monomeric IgG must oligomerize to activate complement via the hexameric C1q complex, and hexamerizing mutants of IgG appear as promising...
3.
Dijkstra D, van de Bovenkamp F, Abendstein L, Zuijderduijn R, Pool J, Kramer C, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(50):e2310666120.
PMID: 38048459
Autoantibodies directed against complement component C1q are commonly associated with autoimmune diseases, especially systemic lupus erythematosus. Importantly, these anti-C1q autoantibodies are specific for ligand-bound, solid-phase C1q and do not bind...
4.
Lameris R, Ruben J, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp F, et al.
Cell Rep Med
. 2023 Mar;
4(3):100961.
PMID: 36868236
Bispecific T cell engagers (bsTCEs) hold great promise for cancer treatment but face challenges due to the induction of cytokine release syndrome (CRS), on-target off-tumor toxicity, and the engagement of...
5.
van de Bovenkamp F, Dijkstra D, van Kooten C, Gelderman K, Trouw L
Mol Immunol
. 2021 Nov;
140:206-216.
PMID: 34735869
C1q is the recognition molecule of the classical pathway of the complement system. By binding to its targets, such as antigen-bound immunoglobulins or C-reactive protein, C1q contributes to the innate...
6.
Temming A, Dekkers G, van de Bovenkamp F, Plomp H, Bentlage A, Szittner Z, et al.
Sci Rep
. 2020 Jul;
10(1):12560.
PMID: 32703963
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Temming A, Dekkers G, van de Bovenkamp F, Plomp H, Bentlage A, Szittner Z, et al.
Sci Rep
. 2019 Jul;
9(1):9995.
PMID: 31292524
The precise mechanisms underlying anti-inflammatory effects of intravenous immunoglobulin (IVIg) therapies remain elusive. The sialylated IgG fraction within IVIg has been shown to be therapeutically more active in mouse models....
8.
Koers J, Derksen N, Ooijevaar-De Heer P, Nota B, van de Bovenkamp F, Vidarsson G, et al.
J Immunol
. 2019 Mar;
202(8):2220-2228.
PMID: 30850477
Abs can acquire -linked glycans in their V regions during Ag-specific B cell responses. Among others, these -linked glycans can affect Ag binding and Ab stability. Elevated -linked glycosylation has...
9.
van de Bovenkamp F, Derksen N, Ooijevaar-De Heer P, Rispens T
J Immunol Methods
. 2019 Feb;
467:58-62.
PMID: 30742813
About 15% of immunoglobulin G (IgG) molecules contain glycans linked to the antigen-binding fragments (Fab arms) in addition to the glycans linked to the crystallizable fragment (Fc tail) of all...
10.
Culver E, van de Bovenkamp F, Derksen N, Koers J, Cargill T, Barnes E, et al.
J Gastroenterol Hepatol
. 2018 Oct;
34(10):1878-1886.
PMID: 30345709
Background And Aim: Immunoglobulin subclass G4-related disease (IgG4-RD) is characterized by an abundance of IgG4 antibodies in the serum and tissue. Glycosylation status of antibodies can impact on immune effector...